Reference to original study:

Guidi G, Casini G, Ripandelli G, Piaggi P, Lucche FD, Sartini M, Loiudice P, Nasini F, Stripe M, Lazzeri S. Residual intraretinal edema after 25-gauge vitrectomy and macular pucker removal: Is intraoperative sustained-release dexamethasone a real treatment option? Retina. 2018;38:993–9. https://doi.org/10.1097/IAE.0000000000001627.

Fig. 1: An infographic looking at the efficacy of the use of intraoperative sustained-release dexamethasone in patients who underwent 25-gauge vitrectomy and macular pucker removal.
figure 1

This randomised controlled trial aimed to investigate the efficacy and safety of intraoperative slow-release dexamethasone implant in vitrectomy plus OZRUDEX implant vs. vitrectomy without OZRUDEX implant for the treatment of idiopathic macular pucker. It found that intraoperative sustained-release dexamethasone implant, a powerful anti-inflammatory agent with significant efficacy in vitrectomized eyes, did not result in a significant change in macular thickness and volume compared with the vitrectomy alone without dexamethasone implant at 6-month follow-up. ERM epiretinal membrane, MP macular pucker.